Belimumab

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF),[4] also known as B-lymphocyte stimulator (BLyS).[5] It is approved in the United States,[6] Canada,[7] and the European Union[3] to treat systemic lupus erythematosus (SLE). The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection o... [wikipedia]